Brief: Kiniksa Pharmaceuticals Announces Global License Agreement With Genentech For Vixarelimab

Kiniksa Pharmaceuticals International

03/08/2022 14:20

Aug 3 (Reuters) - Kiniksa Pharmaceuticals Ltd  KNSA.O :
    * KINIKSA PHARMACEUTICALS ANNOUNCES GLOBAL LICENSE AGREEMENT
WITH
GENENTECH FOR VIXARELIMAB
    * KINIKSA PHARMACEUTICALS LTD - KINIKSA TO RECEIVE $100
MILLION IN
UPFRONT AND NEAR-TERM PAYMENTS
    * KINIKSA PHARMACEUTICALS LTD - KINIKSA IS ELIGIBLE TO
RECEIVE
DEVELOPMENT AND COMMERCIAL MILESTONES AS WELL AS ROYALTIES ON
NET SALES
    * KINIKSA PHARMACEUTICALS LTD - GLOBAL LICENSE INCLUDES
DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO VIXARELIMAB
    * KINIKSA PHARMACEUTICALS LTD - UNDER TERMS OF GLOBAL
LICENSE
AGREEMENT, KINIKSA WILL RECEIVE $100 MILLION IN UPFRONT AND
NEAR-TERM PAYMENTS
    * KINIKSA PHARMACEUTICALS LTD - COMPLETED SCREENING PATIENTS
FOR
PHASE 2B CLINICAL TRIAL OF VIXARELIMAB IN PRURIGO NODULARIS
    * KINIKSA PHARMACEUTICALS - IS ELIGIBLE TO RECEIVE UP TO
ABOUT
$600 MILLION IN CERTAIN CLINICAL, REGULATORY, SALES-BASED
MILESTONES
    * KINIKSA PHARMACEUTICALS LTD - PLANS TO COMPLETE TRIAL BUT
WILL
NO LONGER DISCLOSE DATA IN SECOND HALF OF 2022

Source text for Eikon:  ID:nGNX5GYlS6 
Further company coverage:  KNSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))